Ro CEO Zach Reitano joins the Yahoo Finance Live show to discuss the weight-loss program Ro and its benefits in comparison to weight-loss drugs on the market.

Video Transcript

- Well, if you're paying attention to celebrities and influencers you've probably heard an awful lot about Ozempic, an FDA approved type 2 diabetes drug getting a lot of attention for its use as an off-label weight loss drug. Joining us now is Zach Reitano, the CEO of direct to patient health care company Ro, and Yahoo Finance's health reporter Anjalee Khemlani. Great to see you both.

So in New York City, you can see your ads for the weight loss program which uses Ozempic and other GLP-1 drugs. Zach, tell us specifically how your program works.

ZACH REITANO: Yeah, absolutely. Maybe I'll take a brief step back, and just give you a quick overview of Ro. Ro helps patients achieve their health care goals in the most effective and convenient way. And we've done that by seamlessly integrating a doctor's office pharmacy and labs.

And so for the body program mentioned in the subway campaign, patients come to us and they tell us, I want to lose weight, or I want high quality obesity care. And we deliver an end-to-end service for that. So patients come on. They'll go through a dynamic online visit, and for questions about their medical history, there are challenges with weight, any medications they're on, allergies.

If appropriate, they'll be eligible for a metabolic lab test that they can do at home or in person. And then pending their health history, and those lab tests in consultation with their provider, they'll see if treatment's right for them. If it is, we'll take on the burden and serve as their insurance concierge, and work with them, their provider, and their insurance plan to see if we can get medication covered.

And then the program starts. And that includes one-to-one provider care one-to-one coaching with nurses, weight tracking, ongoing labs, and an educational curriculum to provide high-quality ongoing obesity care.